Free Trial
TSE:ATE

Antibe Therapeutics (ATE) Stock Price, News & Analysis

Antibe Therapeutics logo

About Antibe Therapeutics Stock (TSE:ATE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
167,044 shs
Average Volume
135,475 shs
Market Capitalization
C$15.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATE Stock News Headlines

Volatility Is Rising—But These 2 AI Stocks Could Thrive
2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines. But even in uncertain times, innovation doesn’t slow down. In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles. Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar.
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc ATE
Antibe Announces Early Warrant Exercise Incentive Program
See More Headlines

ATE Stock Analysis - Frequently Asked Questions

Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Antibe Therapeutics investors own include Resverlogix (RVX), Royal Bank of Canada (RY), Tesla (TSLA), Unrivaled Brands (TRTC), Baytex Energy (BTE), Enbridge (ENB) and NVIDIA (NVDA).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:ATE
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-18,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$9.71 million
Price / Cash Flow
0.61
Book Value
C$0.49 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$15.64 million
Optionable
Not Optionable
Beta
0.19
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (TSE:ATE) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners